预测低反应患者的活产:PROsPeR 概念
基于 ESPART 试验数据开发并简化了针对接受重组人 FSH 的低反应患者活产预测模型 PROsPeR,该模型含三个预测因子、分三个评分等级,校准良好时区分度 AUCROC(95%CI)达 0.84(0.79 至 0.88),优于既往已发表模型。
要点
- PROsPeR 含三个预测因子,将低反应患者分为三个评分等级。
- 每恶化一个等级,预测活产率约降至三分之一。
- 校准良好时区分度 AUCROC(95%CI)为 0.84(0.79 至 0.88)。
核心结论
- 该模型针对接受重组人 FSH 的低反应患者,在精确性与简便性之间取得最佳平衡,适合常规实践。
研究设计与样本
- 使用 ESPART 试验数据开发预测低反应患者接受重组人 FSH 后活产的模型。
- 最初分别开发两个模型:一个有既往辅助生殖技术周期数据的患者模型,一个未接受过辅助生殖技术治疗的患者模型。
- 随后衍生出简化的低反应结局预测(PROsPeR)概念。
主要发现
- PROsPeR 考虑三个预测因子,将低反应患者分为三个评分等级,每恶化一个等级预测活产率约降至三分之一。
- 校准良好时区分度 AUCROC(95%CI)达 0.84(0.79 至 0.88),优于既往已发表模型。
- 用 PROsPeR 模型评估 ESPART 研究中同时接受重组人 FSH 和重组人 LH 的患者时区分度较低,AUCROC(95%CI)为 0.66(0.61 至 0.71)。
- 用 PROsPeR 模型评估 ESPART 研究纳入的全部患者时 AUCROC(95%CI)为 0.68(0.61 至 0.72)。
临床怎么用
- 作者结论认为该模型适合常规实践,用于接受重组人 FSH 的低反应患者活产预测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: A number of live-birth predictive models are available, and despite clinical interest these are rarely used owing to poor performance. In addition, no predictive models specifically for poor ovarian responders (POR) are available. The aim of the current project was to develop a clinically applicable tool for predicting live birth for PORs receiving recombinant human FSH [r-hFSH]. DESIGN: A model was developed to predict live birth in PORs receiving r-hFSH, using data from the ESPART trial. Initially, two models were developed separately: one for patients with data from a previous assisted reproductive technology (ART) cycle and one for ART treatment-naïve patients. Subsequently, the simplified Poor Responder Outcome Prediction (PROsPeR) concept was derived. RESULTS: PROsPeR considers three predictors and categorizes PORs into three scores, with predicted the live-birth rate divided by three with each worsening category. When adequately calibrated, a discrimination score up to area under the receiver operating characteristic (AUCROC) (95% CI) of 0.84 (0.79 to 0.88) was observed, which is superior to previously published models. Lower discriminations were observed when the PROsPeR model was used to evaluate the patients who received both r-hFSH and recombinant human LH in the ESPART study (AUCROC [95% CI] 0.66 [0.61 to 0.71]) and when all the patients included in the ESPART study were evaluated (AUCROC [95% CI] 0.68 [0.61 to 0.72]). CONCLUSIONS: This model, specific to PORs receiving r-hFSH, constitutes the best compromise between precision and simplicity, and is suitable for routine practice.
引用
- Lehert P, Chin W, Schertz J, et al. Predicting live birth for poor ovarian responders: the PROsPeR concept. Reprod Biomed Online. 2018. PMID: 29731240. doi:10.1016/j.rbmo.2018.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。